AcquisitionsJul 13, 2026, 04:11 PM
BioMarin Completes Amicus Acquisition for $5.32B
AI Summary
BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics, Inc. on April 27, 2026, for an aggregate transaction value of approximately $5,323.6 million. The acquisition was funded through $3,650.0 million in new borrowings and $1,836.0 million in cash on hand. This amendment provides the audited financial statements of Amicus and unaudited pro forma condensed combined financial information for the combined entity.
Key Highlights
- Acquisition of Amicus Therapeutics, Inc. completed on April 27, 2026.
- Aggregate transaction value for Amicus acquisition was approximately $5,323.6 million.
- Acquisition funded by $3,650.0 million in new borrowings.
- Acquisition also funded by $1,836.0 million in cash on hand.
- Amicus stockholders received $14.50 per share in cash.
- Pro forma combined net product revenues for 2025 were $3,801,969 thousand.
- Pro forma combined net loss for 2025 was $(205,884) thousand.
Price Impact
More from BMRN